Regan Seipp1, Nan Zhang2, Sumi Sukumaran Nair1, Hasan Khamash1, Amit Sharma3, Scott Leischow4, Raymond Heilman1, Mira T Keddis1. 1. Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States of America. 2. Department of Health Science Research, Section of Biostatistics, Mayo Clinic, Phoenix, Arizona, United States of America. 3. Division of Dermatology, Department of Medicine, Mayo Clinic, Phoenix, Arizona, United States of America. 4. Office of Health Care Disparity, Mayo Clinic, Phoenix, Arizona, United States of America.
Abstract
BACKGROUND: The objective is to assess cardiovascular (CV), malignancy, infectious, graft outcomes and tacrolimus levels for the Indigenous patients compared to Whites after kidney transplant (KTx). METHODS: 165 Indigenous and 165 White patients matched for the KTx year at Mayo Clinic Arizona from 2007-2015 were studied over a median follow-up of 3 years. Propensity score was calculated to account for baseline differences. RESULTS: Compared to Whites, Indigenous patients had the following characteristics: younger age, more obesity, diabetes, hypertension, and required dialysis prior to KTx (p<0.01). Indigenous patients had longer hospital stay for KTx, shorter follow-up and lived further from the transplant center (p<0.05). 210 (63.6%) received deceased donor KTx and more Whites received a living donor KTx compared to Indigenous patients (55.2% vs 17.6%, p<0.0001). Post-KTx, there was no difference in the CV event rates. The cumulative incidence of infectious complications was higher among the Indigenous patients (HR 1.81, p = 0.0005, 48.5% vs 38.2%, p = 0.013), with urinary causes as the most common. Malignancy rates were increased among Whites (13.3% vs 3.0%, p = 0.001) with skin cancer being the most common. There was a significant increase in the dose normalized tacrolimus level for the Indigenous patients compared to Whites at 1 months, 3 months, and 1 year post-KTx. After adjustment for the propensity score, there was no statistical difference in infectious or graft outcomes between the two groups but the mean number of emergency room visits and hospitalizations after KTx was significantly higher for Whites compared to Indigenous patients. CONCLUSIONS: Compared to Whites, Indigenous patients have similar CV events, graft outcomes and infectious complications after accounting for baseline differences.
BACKGROUND: The objective is to assess cardiovascular (CV), malignancy, infectious, graft outcomes and tacrolimus levels for the Indigenous patients compared to Whites after kidney transplant (KTx). METHODS: 165 Indigenous and 165 White patients matched for the KTx year at Mayo Clinic Arizona from 2007-2015 were studied over a median follow-up of 3 years. Propensity score was calculated to account for baseline differences. RESULTS: Compared to Whites, Indigenous patients had the following characteristics: younger age, more obesity, diabetes, hypertension, and required dialysis prior to KTx (p<0.01). Indigenous patients had longer hospital stay for KTx, shorter follow-up and lived further from the transplant center (p<0.05). 210 (63.6%) received deceased donor KTx and more Whites received a living donor KTx compared to Indigenous patients (55.2% vs 17.6%, p<0.0001). Post-KTx, there was no difference in the CV event rates. The cumulative incidence of infectious complications was higher among the Indigenous patients (HR 1.81, p = 0.0005, 48.5% vs 38.2%, p = 0.013), with urinary causes as the most common. Malignancy rates were increased among Whites (13.3% vs 3.0%, p = 0.001) with skin cancer being the most common. There was a significant increase in the dose normalized tacrolimus level for the Indigenous patients compared to Whites at 1 months, 3 months, and 1 year post-KTx. After adjustment for the propensity score, there was no statistical difference in infectious or graft outcomes between the two groups but the mean number of emergency room visits and hospitalizations after KTx was significantly higher for Whites compared to Indigenous patients. CONCLUSIONS: Compared to Whites, Indigenous patients have similar CV events, graft outcomes and infectious complications after accounting for baseline differences.
Authors: Nilka Ríos Burrows; Pyone Cho; Kai McKeever Bullard; Andrew S Narva; Paul W Eggers Journal: Am J Public Health Date: 2014-04-22 Impact factor: 9.308
Authors: Moataz E Mohamed; David P Schladt; Weihua Guan; Baolin Wu; Jessica van Setten; Brendan J Keating; David Iklé; Rory P Remmel; Casey R Dorr; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; William S Oetting; Pamala A Jacobson Journal: Am J Transplant Date: 2019-05-13 Impact factor: 8.086
Authors: H A Chakkera; Y-H Chang; J K Bodner; S Behmen; R L Heilman; K S Reddy; D C Mulligan; A A Moss; H Khamash; N Katariya; W R Hewitt; T L Pitta; L A Frassetto Journal: Transplant Proc Date: 2013 Jan-Feb Impact factor: 1.066
Authors: Stacey E Jolly; Suying Li; Shu-Cheng Chen; Andrew S Narva; Claudine T Jurkovitz; Keith C Norris; Michael G Shlipak Journal: Am J Nephrol Date: 2008-11-14 Impact factor: 3.754
Authors: Rachael C Walker; Sally Abel; Annie Reynolds; Suetonia C Palmer; Curtis Walker; David C Tipene-Leach Journal: Int J Equity Health Date: 2019-12-30